New hope for tough cancers: drug targets BRCA mutations
NCT ID NCT02286687
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This study tests a drug called talazoparib in 150 people with advanced cancers that have not responded to standard treatments. The drug works by blocking an enzyme that helps cancer cells survive, specifically targeting tumors with changes in BRCA or related genes. The goal is to see if the drug can shrink tumors or slow their growth, offering a new option for patients with these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 GENE MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.